Company intelligence / Profile preview

CytoImmune Therapeutics

Duarte, California, United Statescytoimmune.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 1

Overview

CytoImmune Therapeutics has developed proprietary platforms to engineer off-the-shelf allogeneic NK cell therapies that directly attack tumor cells while stimulating both innate and adaptive immunity. Their lead programs are in clinical development for solid tumors such as non-small cell lung cancer. The company leverages advanced manufacturing capabilities in Puerto Rico to rapidly deliver therapies within days rather than weeks. Early results focus on safety/feasibility; detailed efficacy data have not yet been published.[2][3][7]

Therapeutic areas: OncologyImmunology
Modalities: Engineered allogeneic natural killer (NK) cells (including CAR-NK™)Bispecific Killer Engager (BiKE) molecules
Industry: Biotech

Drug pipeline

8 assets

CYTO NK-203

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Licensed core technology from City of Hope National Medical Center laboratories of Drs. Michael Caligiuri & Jianhua Yu[8]. No major pharma partnerships publicly disclosed.

Beyond the preview

Go deeper on CytoImmune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoImmune Therapeutics.

Explore the full profile